Gerresheimer, a pharmaceutical and healthcare packaging company based in Germany, will expand its Queretaro facility in Mexico.
The expansion will increase the production capacities for ready-to-fill (RTF) syringes, catering to the North American market’s demand for high-quality syringes.
Recommended White Papers
Recommended Buyers Guides
The prefillable glass syringes are suitable for administering injectable biopharmaceuticals such as glucagon-like peptide-1-based drugs used in managing obesity.
The expansion commenced with a ground-breaking ceremony in November 2023. Gerresheimer is investing approximately €100m ($106m) in the project, which is expected to create approximately 270 new job opportunities.
The building is expected to be completed by mid-2024, with production anticipated to begin in the second quarter (Q2) of 2025.
Location
The plant is situated at Av. Coahuila No. 9, Zona Industrial Benito Juarez, in Santiago de Queretaro, Mexico.
Gerresheimer’s Queretaro facility expansion details
The expansion will involve the development of a new production building with a total area of 7,500m², enabling Gerresheimer to increase its manufacturing capacity significantly.
The new building will be equipped with ten glass-forming machines and multiple needle assembly and RTF production lines, utilising the latest automation and quality assurance technologies.
Syringe preparation processes, including washing and packaging, will be conducted in clean rooms ranging from International Organization for Standardization (ISO) 8 to ISO 6 class.
The expansion will increase the manufacturing capacity by several hundred million RTF syringes annually for the North American market.
Details of Gerresheimer’s existing Queretaro facility
Gerresheimer’s existing facility in Queretaro specialises in the production of primary pharmaceutical glass packaging.
Its product line includes ampoules, serum vials, injection vials, screw thread vials, RTF syringes, and cartridges, with Type I glass available in both clear and amber.
The plant has a workforce of approximately 1,000 employees and holds several ISO certifications, including ISO 13485, ISO 9001, ISO 15378, and ISO 45001.
Gerresheimer product portfolio
Gerresheimer’s product portfolio encompasses pharmaceutical containment solutions, drug delivery systems, medical devices, and health industry solutions.
The range extends from digital therapy support systems and medication pumps to syringes, pens, auto-injectors, inhalers, vials, ampoules, tablet containers, and bottles for infusions, droppers, and syrups.
Gerresheimer’s solutions are categorised into Gx Elite, offering top-tier quality and protection for sensitive drugs; Gx Advance, which provides enhanced quality for increased efficiency in fill-and-finish processes; and Gx Value, a trusted solution in pharmaceutical quality.
Gerresheimer’s innovative offerings include Gx Elite Glass, Gerresheimer Autoinjector, Gx RTF Vials, Micro Pump technology, DropControl, Gx CyClic sustainable refill jar for cosmetics, and Ophthalmic plus jars suitable for individuals with limited upper limb mobility.
The portfolio also includes prefillable glass and polymer syringes, the Gx Elite RTF ClearJect polymer syringe, silicone-oil-free syringe systems, the Gx Elite RTF Syringe, and the Gx SensAir on-body drug delivery device.
The company makes plastic syringes out of cyclic olefin polymer.
Marketing commentary on Gerresheimer
Headquartered in Germany, Gerresheimer employs more than 11,000 people and operates in two segments, plastics and devices, and primary packaging glass.
The plastics and devices segment delivers both standard and customised drug delivery products, including insulin pens and inhalers.
The primary packaging glass segment is dedicated to the production of glass packaging such as jars, ampoules, and injection vials.
With a commitment to ensuring the safe delivery and reliable administration of drugs, Gerresheimer maintains a global presence with 36 production sites across 16 countries in Europe, America, and Asia.
Its global footprint allows for local production designed to regional market needs.
The company is also expanding its production capacities in various product segments across Germany, Belgium, North Macedonia, the Czech Republic, and the US, reinforcing its role as a key partner to the pharmaceutical, biotech, and cosmetics industries by producing locally for regional markets.
